The Prostate Cancer Androgen Receptor Splice Variant 7 Biomarker Study- A multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer

• Study stage: Closed
• Sponsor:  The Newcastle Upon Tyne Hospitals NHS Foundation Trust
• Funder:  NIHR – Research for Patient Benefit
• Therapeutic area: Cancer and Neoplasm
• Type of study:  Non clinical intervention

Aim: To determine the feasibility of a definitive randomised control trial to evaluate the clinical utility of an AR-V7 blood biomarker assay in personalising treatment for men with mCRPC in UK NHS clinical practice.

Primary Outcome:

To establish if it is feasible to conduct a definitive large-scale pragmatic trial comparing AR-V7 biomarker-driven management with the current standard of care in patients with metastatic Castration-Resistant Prostate Cancer.

• Population: Adult
• Design: RCT
• Setting: Secondary Care
• Planned Sample Size: 70